NRSN — NeuroSense Therapeutics Ltd.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1875091 ·
Last close
$1.51
Market Cap
$2.86M
52W High
$25.40
52W Low
$1.10
ADV30
38,629
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | 896,000 | 231,000 | 2,999,000 |
| Dec 2025 | — | — | — | — | 1,028,000 | 166,000 | 2,588,000 |
| Jun 2025 | — | — | — | — | 1,684,000 | 666,000 | 2,203,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-51,348,000
Inventory
—
Receivables
$540,000
ST Investments
—
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
2
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -11,085,000 | -11,125,000 | 1,028,000 | 2,588,000 | -1,560,000 | -7,671,000 |
| Dec 2024 | 0 | -9,902,000 | -10,210,000 | 4,575,000 | 1,992,000 | 2,583,000 | -10,135,000 |
| Dec 2023 | 0 | -12,049,000 | -10,107,000 | 3,185,000 | 4,944,000 | -1,759,000 | -8,354,000 |
| Dec 2022 | 0 | -10,554,000 | -10,492,000 | 7,710,000 | 2,091,000 | 5,619,000 | -7,616,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-13.50
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GELS | Gelteq Ltd | $2.88M | $0.27 | — |
| MDCX | Medicus Pharma Ltd. | $2.89M | $1.52 | — |
| DRMA | Dermata Therapeutics, Inc. | $2.81M | $0.57 | — |
| APUS | Apimeds Pharmaceuticals US, Inc. | $2.94M | $1.95 | — |
| PPBT | PURPLE BIOTECH LTD. | $2.78M | $1.71 | — |
News headlines (Yahoo Finance, 1h cache)
NeuroSense to Strengthen PrimeC Canadian ALS Submission With New NfL Data
2026-11-02 14:00 · Yahoo
NeuroSense to Present Integrated Clinical and Biomarker Evidence Shaping PrimeC's Phase 3 Development at NEALS 2026
2026-10-29 15:30 · Yahoo
NeuroSense Files U.S. Patent Application for Traumatic Brain Injury
2026-10-19 12:25 · Yahoo
NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones
2026-10-13 12:30 · Yahoo
NeuroSense Provides Update on Nasdaq Listing Compliance
2026-10-02 20:15 · Yahoo
NeuroSense to Participate in the 5th Annual ROTH Healthcare Opportunities Conference
2026-09-28 16:43 · Yahoo
NeuroSense Provides Business Update and Progress for the First Half of 2026
2026-09-25 20:30 · Yahoo
NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference
2026-09-10 13:00 · Yahoo
NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS
2026-08-31 12:45 · Yahoo
NeuroSense Issues CEO Letter to Shareholders
2026-08-13 13:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.